ETM
MYGN icon

Euclidean Technologies Management’s Myriad Genetics MYGN Stock Holding History

Euclidean Technologies Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-3,100
Closed -$116K – 58
2016
Q1 		$116K Sell
3,100
-37,817
-92% -$1.42M 0.12% 52
2015
Q4 		$1.77M Sell
40,917
-26,362
-39% -$1.11M 1.9% 36
2015
Q3 		$2.52M Hold
67,279
– – 2.64% 2
2015
Q2 		$2.29M Buy
67,279
+3,595
+6% +$122K 2.15% 13
2015
Q1 		$2.25M Buy
63,684
+37,322
+142% +$1.34M 2.05% 30
2014
Q4 		$898K Buy
+26,362
New +$935K 0.84% 34

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Euclidean Technologies Management's MYGN Position: Q2 2016 in Review

Euclidean Technologies Management sold out of Myriad Genetics (MYGN) in Q2 2016, closing a stake of 3,100 shares — an estimated $116K sold.

Euclidean Technologies Management first reported a position in MYGN in Q4 2014 and held it in 6 quarters. The position peaked at $2.52M in Q3 2015. 252 funds tracked by Wall St. Rank hold MYGN as of Q2 2016.

  • Euclidean Technologies Management reported no remaining Myriad Genetics position as of Q2 2016 after selling out during the quarter.
  • Euclidean Technologies Management sold 3,100 Myriad Genetics shares in Q2 2016, an estimated $116K.
  • Euclidean Technologies Management first reported a position in Myriad Genetics in Q4 2014 and held it in 6 quarters.
  • Euclidean Technologies Management's Myriad Genetics position peaked at $2.52M in Q3 2015.
  • 252 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2016.

Based on Euclidean Technologies Management's 13F filing for Q2 2016, filed 12 Aug 2016.